A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps

Inclusion Criteria: 1. Age 18-75 years old. 2. With bilateral chronic rhinosinusitis with nasal polyposis. 3. Nasal Polyp Score ≥4 (minimum score of 2 per nasal cavity) at baseline. 4. Nasal congestion score ≥2 at baseline. 5. Patients who have received systemic corticosteroids (SCS) treatment within 2 years before screening, and/or have contraindications or intolerance to SCS treatment, and/or received surgical for nasal polyps more than 6 months before screening. 6. Have been using intranasal corticosteroids (INCS) at a stable dose for at least 4 weeks before screening. 7. Symptoms of nasal obstruction and additional symptoms such as loss of smell or rhinorrhea should be present for at least 4 weeks before screening. 8. Good adherence. Exclusion Criteria: 1. Not enough washing out period for prior biological therapy (within 10 weeks or 5 half-lives \[whichever is longer\] before baseline). 2. Use of systemic immunosuppressants for inflammatory diseases or autoimmune diseases within 8 weeks or 5 half-lives before baseline (whichever is longer). 3. Initiation of leukotriene receptor antagonist treatment, oral glucocorticoid treatment, or traditional Chinese medicine treatment for chronic rhinosinusitis within 4 weeks before baseline. 4. Subjects who have undergone surgery that changed the nasal structure and cannot be evaluated for Nasal Polyp Score. 5. Participants with a forced expiratory volume in 1 second (FEV1) ≤50% of predicted normal during screening/run-in period. 6. Hypersensitivity to MFNS or anti-IL-4R monoclonal antibodies or stapokibart components. 7. Concomitant with other poorly controlled serious diseases or recurrent chronic diseases. 8. Women who are pregnant, breastfeeding, or planning either during the study.